Loading...
01/11 07:32
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call highlights strong potential for gedatolisib with a $5 billion market opportunity and extended patent exclusivity. Despite increased losses due to higher R&D and operational costs, the company has a solid cash position to support future growth. The Q&A section indicates positive analyst sentiment and excitement around clinical trial progress and market strategy. While some details remain unclear, the overall outlook is promising, suggesting a positive stock price movement.
Net Loss $43.8 million for Q3 2025, compared to $29.8 million for Q3 2024. This represents an increase of $14 million year-over-year. The increase is attributed to higher research and development expenses and general and administrative expenses.
Non-GAAP Adjusted Net Loss $37.2 million for Q3 2025, compared to $27.6 million for Q3 2024. This represents an increase of $9.6 million year-over-year. The increase is due to higher operational costs, including employee and consulting expenses.
Research and Development Expenses $34.9 million for Q3 2025, compared to $27.6 million for Q3 2024. This represents an increase of $7.3 million year-over-year. The increase is primarily due to $5.6 million in higher employee and consulting expenses, with $3.2 million related to commercial headcount additions and launch activities, and $1.7 million for clinical trial support.
General and Administrative Expenses $7.9 million for Q3 2025, compared to $2.5 million for Q3 2024. This represents an increase of $5.4 million year-over-year. The increase is mainly due to $4.9 million in higher employee and consulting expenses, including $4 million in non-cash stock-based compensation, and $0.5 million in professional fees and administrative costs.
Net Cash Used in Operating Activities $44.8 million for Q3 2025, compared to $20.6 million for Q3 2024. This represents an increase of $24.2 million year-over-year. The increase is attributed to higher operational and clinical trial expenses.
Cash, Cash Equivalents, and Short-term Investments $455 million as of the end of Q3 2025. This includes $287 million raised from public offerings and $27.8 million from a term loan facility.
Gedatolisib as a new standard of care: Significant progress in clinical and regulatory milestones for gedatolisib, including positive Phase III trial results for HR-positive, HER2-negative advanced breast cancer. FDA accepted NDA submission under real-time oncology review program.
Clinical trial results: Phase III VIKTORIA-1 trial showed gedatolisib triplet improved median progression-free survival (PFS) by 7.3 months compared to fulvestrant. Gedatolisib doublet improved PFS by 5.4 months. Results set new benchmarks in HR-positive, HER2-negative advanced breast cancer.
Prostate cancer trial: Phase I/II trial of gedatolisib with darolutamide in metastatic castration-resistant prostate cancer showed favorable results with median radiographic PFS of 9.1 months.
Market potential for gedatolisib: Estimated total addressable market for gedatolisib in second-line HR-positive, HER2-negative advanced breast cancer is $5-6 billion. Potential peak revenues estimated at $2.5-3 billion.
Commercial launch preparation: Significant progress in preparing for gedatolisib launch, including hiring key personnel, defining sales territories, and engaging with payers and oncologists.
Financial position: Raised $287 million through convertible notes, common stock, and warrants. Amended term loan facility to $500 million, with $350 million committed capital. Cash reserves expected to fund operations through 2027.
Increased R&D and G&A expenses: R&D expenses increased by $7.3 million, primarily due to employee and consulting costs. G&A expenses rose by $5.4 million, driven by stock-based compensation and professional fees.
Strategic focus on oncology: Focused on advancing gedatolisib for breast and prostate cancer indications. Preparing for potential FDA approval and commercial launch in 2026.
Regulatory Risks: The company is preparing for FDA approval of gedatolisib in 2026. Any delays or issues in the approval process could adversely impact the company's strategic plans and financial performance.
Clinical Trial Risks: The success of the company's future operations heavily depends on the outcomes of ongoing clinical trials, such as the VIKTORIA-2 study and the Phase I/II trial for prostate cancer. Any unfavorable results or delays in these trials could hinder the company's progress.
Financial Risks: The company reported a net loss of $43.8 million for Q3 2025, an increase from the previous year. High R&D and G&A expenses, coupled with reliance on convertible notes and term loans, could strain financial resources if revenue generation is delayed.
Market Penetration Risks: While optimistic about market share for gedatolisib, there is a risk that the company may not achieve the projected penetration or revenue targets due to competition or unforeseen market dynamics.
Operational Risks: The company is ramping up for a commercial launch, including hiring and infrastructure expansion. Any missteps in execution or delays in launch preparations could impact operational efficiency and market readiness.
Supply Chain Risks: Potential disruptions in the supply chain for gedatolisib or other products could delay production and distribution, affecting the company's ability to meet market demand.
FDA Approval and Launch of Gedatolisib: Celcuity expects to complete the submission of the New Drug Application (NDA) for gedatolisib under the FDA's real-time oncology review program this quarter, with potential FDA approval anticipated in 2026. Preparations for the commercial launch of gedatolisib are underway, with significant progress in building the organization and internal systems required for a commercial-stage company.
Market Potential and Revenue Projections for Gedatolisib: The company estimates the total addressable market for gedatolisib in the second-line setting for HR-positive, HER2-negative advanced breast cancer to be $5 billion to $6 billion. Based on anticipated market penetration, Celcuity projects potential peak revenues of $2.5 billion to $3 billion for this indication.
Clinical Trials and Data Timelines: Top-line data from the PIK3CA mutant cohort of the Phase III VIKTORIA-1 trial is expected in late Q1 2026 or during Q2 2026. Enrollment for the VIKTORIA-2 Phase III trial, evaluating gedatolisib as a first-line treatment, is ongoing. The company is also advancing a Phase I/II trial for gedatolisib in combination with darolutamide for metastatic castration-resistant prostate cancer.
Financial Outlook and Funding: Celcuity has raised $287 million through offerings and increased its term loan facility to $500 million, providing financial flexibility to support operations through 2027. This funding will be used for clinical trials, commercial launch preparations, and other strategic initiatives.
The selected topic was not discussed during the call.
The earnings call highlights strong potential for gedatolisib with a $5 billion market opportunity and extended patent exclusivity. Despite increased losses due to higher R&D and operational costs, the company has a solid cash position to support future growth. The Q&A section indicates positive analyst sentiment and excitement around clinical trial progress and market strategy. While some details remain unclear, the overall outlook is promising, suggesting a positive stock price movement.
The earnings call presents mixed signals: collaboration with renowned institutions and a solid cash position are positives, but increased losses and R&D expenses raise concerns. The Q&A revealed management's evasiveness on critical safety and competitive landscape details, which may dampen investor confidence. Despite potential in new drug trials, the lack of clear guidance and increased expenses suggest a neutral sentiment. Without market cap data, we assume a moderate reaction.
The earnings call reveals significant financial challenges, including increased net loss and operational expenses, without any share repurchase program to boost shareholder confidence. Despite optimistic market potential, regulatory and market adoption risks remain high. The Q&A section highlights management's reluctance to provide specific projections, which can increase investor uncertainty. No new partnerships or positive catalysts were announced. Overall, the financial outlook and management's evasive responses contribute to a negative sentiment, likely leading to a stock price decline in the range of -2% to -8%.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
